<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482677</url>
  </required_header>
  <id_info>
    <org_study_id>CE6</org_study_id>
    <secondary_id>CAN-NCIC-CE6</secondary_id>
    <secondary_id>EORTC-26062-22061</secondary_id>
    <secondary_id>TROG 08.02</secondary_id>
    <secondary_id>SPRI-CAN-NCIC-CE.6</secondary_id>
    <secondary_id>CDR0000547163</secondary_id>
    <nct_id>NCT00482677</nct_id>
    <nct_alias>NCT00493207</nct_alias>
  </id_info>
  <brief_title>Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving radiation therapy
      together with temozolomide may kill more tumor cells. It is not yet known whether radiation
      therapy and temozolomide are more effective than radiation therapy alone in treating
      glioblastoma multiforme.

      PURPOSE: This randomized phase III trial is studying radiation therapy and temozolomide to
      see how well they work compared with radiation therapy alone in treating patients with newly
      diagnosed glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare overall survival rates in older patients with newly diagnosed glioblastoma
           multiforme treated with short-course radiotherapy with or without temozolomide.

      Secondary

        -  Compare progression-free survival of patients treated with these regimens.

        -  Compare the nature, severity, and frequency of adverse events in patients treated with
           these regimens.

        -  Compare the quality of life of patient treated with these regimens.

        -  Determine the methylation status of the O6-methylguanine-DNA methyltransferase promoter.

      OUTLINE: This is a multicenter, randomized study. Patients are stratified according to
      center, age (65-70 years vs 71-75 years vs ≥ 76 years), ECOG performance status (0-1 vs 2),
      and extent of resection at surgery (biopsy only vs complete or incomplete resection).
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo radiotherapy once daily on days 1-5, 8-12, and 15-19 in the
           absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients undergo radiotherapy as in arm I and receive oral temozolomide once
           daily on days 1-25.

      Beginning 4 weeks after completion of radiotherapy and temozolomide, patients receive
      adjuvant oral temozolomide once daily on days 1-5. Treatment with temozolomide alone repeats
      every 28 days for up to 12 months in the absence of disease progression or unacceptable
      toxicity.

      Patients complete quality of life questionnaires at baseline and periodically during study
      treatment.

      Tissue samples are collected at baseline and analyzed for methylation status of the
      O6-methylguanine-DNA methyltransferase promoter.

      After completion of study treatment, patients are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from date of randomization to the date of death of any causes, or censored at last known alive date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 years</time_frame>
    <description>Evaluated according to CTCAE V3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter</measure>
    <time_frame>7 years</time_frame>
    <description>Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">562</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temozolomide and short course radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Short course radiation alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.</description>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
    <description>A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms</description>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>prior to randomization until end of study</description>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Short course radiotherapy</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histopathologically confirmed glioblastoma multiforme

               -  Grade IV disease by WHO classification

               -  Newly diagnosed disease

          -  Initial diagnostic surgery or biopsy performed within the past 4 weeks

          -  Not a candidate for standard radiotherapy (60Gy/30 fractions over 6 weeks) in
             combination with temozolomide

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute granulocyte count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

          -  ALT and AST &lt; 2.5 times ULN

          -  No known hypersensitivity to temozolomide or compounds with similar chemical
             composition to temozolomide

          -  No history of other malignancies except adequately treated nonmelanoma skin cancer,
             curatively treated in situ cancer of the cervix, or other curatively treated solid
             tumors with no evidence of disease for at least 5 years

          -  No serious active infection (e.g., wound infection requiring parenteral antibiotics)
             or other serious underlying medical conditions that would preclude study treatment

          -  No other condition (e.g., psychological or geographical) that would preclude study
             compliance

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy

          -  No prior radiotherapy

          -  No prior or concurrent investigational therapy

          -  No concurrent surgical procedures for tumor debulking

          -  No concurrent stereotactic boost radiotherapy

          -  No other concurrent chemotherapy, immunotherapy, or biological therapy

          -  No concurrent epoetin alfa

          -  Concurrent corticosteroids allowed provided the patient has been on a stable or
             decreasing dose for at least 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Normand Laperriere, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James R. Perry, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alba A. Brandes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Bellaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Menten, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier regional de Trois-Rivieres</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastro - Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <zip>6201</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Italy</country>
  </removed_countries>
  <results_reference>
    <citation>Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.</citation>
    <PMID>28296618</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide</title>
          <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
        </group>
        <group group_id="P2">
          <title>Radiation</title>
          <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide</title>
          <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
        </group>
        <group group_id="B2">
          <title>Radiation</title>
          <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="281"/>
            <count group_id="B2" value="281"/>
            <count group_id="B3" value="562"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="65" upper_limit="90"/>
                    <measurement group_id="B2" value="73" lower_limit="65" upper_limit="88"/>
                    <measurement group_id="B3" value="73" lower_limit="65" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>&quot;The ECOG Scale of Performance Status ranges between 0 (Fully active, able to carry on all pre-disease performance without restriction) and 5 (Dead).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0, 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Biopsy only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete/incomplete resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Status Examination</title>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="5" upper_limit="30"/>
                    <measurement group_id="B2" value="27" lower_limit="7" upper_limit="30"/>
                    <measurement group_id="B3" value="27" lower_limit="5" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Time from date of randomization to the date of death of any causes, or censored at last known alive date.</description>
        <time_frame>7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
          </group>
          <group group_id="O2">
            <title>Radiation</title>
            <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from date of randomization to the date of death of any causes, or censored at last known alive date.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" lower_limit="8.31" upper_limit="10.25"/>
                    <measurement group_id="O2" value="7.62" lower_limit="6.97" upper_limit="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date.</description>
        <time_frame>7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
          </group>
          <group group_id="O2">
            <title>Radiation</title>
            <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" lower_limit="4.60" upper_limit="6.21"/>
                    <measurement group_id="O2" value="3.94" lower_limit="3.52" upper_limit="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Evaluated according to CTCAE V3.0</description>
        <time_frame>7 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter</title>
        <description>Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter</description>
        <time_frame>7 years</time_frame>
        <population>Patients with MGMT promoter methylated.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
          </group>
          <group group_id="O2">
            <title>Radiation</title>
            <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter</title>
          <description>Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter</description>
          <population>Patients with MGMT promoter methylated.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47" lower_limit="10.25" upper_limit="15.31"/>
                    <measurement group_id="O2" value="7.69" lower_limit="5.82" upper_limit="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide</title>
          <description>Temozolomide and short course radiation
temozolomide: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study</description>
        </group>
        <group group_id="E2">
          <title>Radiation</title>
          <description>Short course radiation alone
DNA methylation analysis: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
quality-of-life assessment: prior to randomization until end of study
Radiation: Short course radiotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Cardiac/heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN II</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI Lower GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI Rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Perforation, GI Colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Perforation, GI Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ulcer, GI Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Death Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Death Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Gait/walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically) Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically) Peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Blood</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Brain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Lung</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Soft tissue NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ADH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint-function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Extremity-upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Left-sided</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Right-sided</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>CNS necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>CSF leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Involuntary movement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN VII</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial CN VIII</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pyramidal tract dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Agitation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Personality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU Kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU Prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary Nose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing (without monitoring program)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Gait/walking</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Radiation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness Extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Muscle weakness Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Muscle</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pain Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Agitation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Mood alteration Depression</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keyue Ding</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>613-5336430</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

